1. Home
  2. TFSL vs IOVA Comparison

TFSL vs IOVA Comparison

Compare TFSL & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TFSL
  • IOVA
  • Stock Information
  • Founded
  • TFSL 1938
  • IOVA 2007
  • Country
  • TFSL United States
  • IOVA United States
  • Employees
  • TFSL N/A
  • IOVA N/A
  • Industry
  • TFSL Savings Institutions
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TFSL Finance
  • IOVA Health Care
  • Exchange
  • TFSL Nasdaq
  • IOVA Nasdaq
  • Market Cap
  • TFSL 3.8B
  • IOVA 3.6B
  • IPO Year
  • TFSL 2007
  • IOVA N/A
  • Fundamental
  • Price
  • TFSL $13.43
  • IOVA $10.38
  • Analyst Decision
  • TFSL Hold
  • IOVA Strong Buy
  • Analyst Count
  • TFSL 2
  • IOVA 10
  • Target Price
  • TFSL $14.00
  • IOVA $24.80
  • AVG Volume (30 Days)
  • TFSL 199.0K
  • IOVA 6.0M
  • Earning Date
  • TFSL 10-24-2024
  • IOVA 11-05-2024
  • Dividend Yield
  • TFSL 8.52%
  • IOVA N/A
  • EPS Growth
  • TFSL N/A
  • IOVA N/A
  • EPS
  • TFSL 0.28
  • IOVA N/A
  • Revenue
  • TFSL $305,488,000.00
  • IOVA $32,772,000.00
  • Revenue This Year
  • TFSL N/A
  • IOVA $13,836.92
  • Revenue Next Year
  • TFSL N/A
  • IOVA $183.20
  • P/E Ratio
  • TFSL $47.21
  • IOVA N/A
  • Revenue Growth
  • TFSL N/A
  • IOVA 13669.75
  • 52 Week Low
  • TFSL $10.97
  • IOVA $3.21
  • 52 Week High
  • TFSL $15.25
  • IOVA $18.33
  • Technical
  • Relative Strength Index (RSI)
  • TFSL 56.71
  • IOVA 52.85
  • Support Level
  • TFSL $13.04
  • IOVA $8.80
  • Resistance Level
  • TFSL $13.55
  • IOVA $10.93
  • Average True Range (ATR)
  • TFSL 0.26
  • IOVA 0.67
  • MACD
  • TFSL 0.01
  • IOVA -0.08
  • Stochastic Oscillator
  • TFSL 79.41
  • IOVA 55.33

About TFSL TFS Financial Corporation

TFS Financial Corp is the holding company for the Third Federal Savings and Loan Association of Cleveland. The company's ownership in the savings and loan association is its primary business activity. The association's principal business consists of originating and servicing residential real estate mortgage loans and attracting retail savings deposits. It does so by offering products with competitive rates and yields. The company also operates Third Capital, a wholly owned subsidiary that serves as a holding company or as an investor in vehicles such as private equity funds. Third Capital has interests in lease transactions of commercial buildings, title agencies providing escrow and settlement services, and reinsurance of private mortgage insurance on residential loans.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: